GLS and hepatocellular carcinoma: The GLS1 inhibitor 968 not only blocks reprogrammed metabolism of HCC cells, but also sensitizes ROS-induced cell death via disrupting redox homeostasis, and thus might reduce the dose of DHA to a more clinical relevant level.